2018
- Acquisition of the PRI-002, PRI-003 and PRI-004 IP portfolio from Forschungszentrum Jülich
- Successful completion of the first-in-human phase I SAD clinical trial for PRI-002
- Start of the Phase I MAD clinical trial for PRI-002 in December 2018
2017
- Founding of Priavoid
- Initiation of series A financing
2013
- Basic Research at Forschungszentrum Jülich
- Research funding by Forschungszentrum Jülich, Helmholtz Gesellschaft, HHU Düsseldorf, VW Stiftung